Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00457171
Status:
TERMINATED
Last Update Posted:
2009-05-18
First Post:
2007-04-04
Brief Title:
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Phase III Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X an Oral ICAM-1 and E-Selectin Inhibitor
Status:
TERMINATED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this double blind placebo controlled study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X and to provide preliminary pharmacokinetics and safetytolerability of 14 days administration of GI270384X in patients with mild to moderate active ulcerative colitis UC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None